Status:
COMPLETED
CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Leukemia, Acute Lymphoblastic
Lymphoblastic Leukemia, Acute, Childhood
Eligibility:
All Genders
3-25 years
Brief Summary
Study Description: This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy. Objectives: Primary To evaluate the Response Free Survival (...
Detailed Description
Study Description: This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy. Objectives: Primary To evaluate the Response Free Survival (...
Eligibility Criteria
Inclusion
- Subjects will not be recruited for this study; however, up to 210 subjects records will be selected from treatment protocols who received CAR therapy for B-ALL. Subject who opted out of the future use of his/her data will be excluded. The subjects enrolled to a CAR T cell therapy treatment protocol within the Pediatric Oncology Branch unless, are \< 25 years of age at the time of diagnosis and must have received prior a CAR T-cell product.
Exclusion
Key Trial Info
Start Date :
October 14 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 29 2024
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT05440409
Start Date
October 14 2021
End Date
October 29 2024
Last Update
June 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute (NCI)
Bethesda, Maryland, United States, 20892